CARMEL,
Ind., April 3, 2024 /PRNewswire/ -- Syra
Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a
healthcare consulting company with a mission to improve healthcare
by providing innovative services and technology solutions,
announced today that Pearl Institutional Review Board (IRB) has
approved the Company's research study protocol for "Syrenity," Syra
Health's prevention-focused mental and behavioral health
platform.
Syrenity is evidence-based and designed to empower users to take
control over their mental health via continual monitoring
through assessments, cognitive
therapy interventions, and telehealth access to a
therapist.
Syra Health launched Syrenity in October of 2023, with a focus
on selling the product to employers looking to support the mental
health of their employees; colleges and universities who want to
support the mental health of their students; and payer
organizations supporting the mental health of their
members. Organizations pay a monthly fee, based on the number
of Syrenity users.
The research study will be performed by third-party university
researchers and practicing psychologists who will enroll
approximately 300 people with moderate or worse depression
severity. Participants will be randomly divided into two cohorts,
one with access to Syrenity and the other without. This two-month
study will examine the efficacy of the Syrenity app and determine
in what ways the app helped the users improve their mental
well-being. The study's results will be targeted for publication in
a scientific journal.
"We are proud that the protocol has been accepted by the
institutional review board tasked with ensuring this randomized
control trial meets all requirements," said Dr. Srikant Devaraj, Vice President of Health
Analytics and President of the Mental and Behavioral Health
business unit, Syra Health. "This empirical research study is the
right way to show if Syrenity is helping engage users and
proactively lowering mental health symptoms. This research study
will enhance the credibility of our Syrenity solution."
Through the Syrenity app, users can schedule health activities
and set goals for their mental health. Syrenity's humanized AI
companion uses sentiment analysis and empathy for frequent chatting
to help the user overcome obstacles and track their progress. At
any point in time, users can navigate a crisis by pushing an
emergency button in the upper right-hand corner of the screen which
immediately calls the Crisis and Suicide Lifeline.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some
of healthcare's most significant challenges in areas such
as behavioral and mental health, digital health,
and population health, by providing innovative services and
technology solutions. Syra Health's products and services are
centered on prevention, improved access, and affordable care. Syra
Health supplies its solutions to payers, providers, life sciences
organizations, academic institutions, and government. For more
information, please visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations,
plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements relating to the expected use of proceeds,
the Company's operations and business strategy and the Company's
expected financial results. The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. The forward-looking
statements contained in this press release are based on
management's current expectations and are subject to substantial
risks, uncertainty and changes in circumstances. Investors should
read the risk factors set forth in our registration statement on
Form S-1 and other periodic reports filed with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and, except as
required by federal securities laws, the Company specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
For more information, please contact:
For Media Inquiries:
Christine
Drury
Communications and Marketing Director
Syra Health
463-345-5180
christined@syrahealth.com
For Investor Inquiries:
Ben
Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/syra-healths-syrenity-research-study-protocol-approved-by-institutional-review-board-302106524.html
SOURCE Syra Health
